341 related articles for article (PubMed ID: 25590436)
21. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis.
Safdar A; Ma J; Saliba F; Dupont B; Wingard JR; Hachem RY; Mattiuzzi GN; Chandrasekar PH; Kontoyiannis DP; Rolston KV; Walsh TJ; Champlin RE; Raad II
Medicine (Baltimore); 2010 Jul; 89(4):236-244. PubMed ID: 20616663
[TBL] [Abstract][Full Text] [Related]
22. Role of urine neutrophil gelatinase-associated lipocalin in the early diagnosis of amphotericin B-induced acute kidney injury.
Rocha PN; Macedo MN; Kobayashi CD; Moreno L; Guimarães LH; Machado PR; Badaró R; Carvalho EM; Glesby MJ
Antimicrob Agents Chemother; 2015 Nov; 59(11):6913-21. PubMed ID: 26303800
[TBL] [Abstract][Full Text] [Related]
23. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
24. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
[TBL] [Abstract][Full Text] [Related]
25. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
Cannon JP; Fiscella R; Pattharachayakul S; Garey KW; De Alba F; Piscitelli S; Edward DP; Danziger LH
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2112-7. PubMed ID: 12714650
[TBL] [Abstract][Full Text] [Related]
26. COMPARATIVE EFFECTIVENESS AND SAFETY BETWEEN AMPHOTERICIN B LIPID-FORMULATIONS: A SYSTEMATIC REVIEW.
Grazziotin LR; Moreira LB; Ferreira MAP
Int J Technol Assess Health Care; 2018 Jan; 34(3):343-351. PubMed ID: 29897025
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.
Sidhu R; Lash DB; Heidari A; Natarajan P; Johnson RH
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686150
[TBL] [Abstract][Full Text] [Related]
28. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations.
Andrew EC; Curtis N; Coghlan B; Cranswick N; Gwee A
Br J Clin Pharmacol; 2018 May; 84(5):1006-1012. PubMed ID: 29352486
[TBL] [Abstract][Full Text] [Related]
29. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.
Falagas ME; Karageorgopoulos DE; Tansarli GS
PLoS One; 2013; 8(10):e77075. PubMed ID: 24204739
[TBL] [Abstract][Full Text] [Related]
30. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Garbino J; Markham L; Matulionyte R; Rives V; Lew D
Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
[TBL] [Abstract][Full Text] [Related]
31. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
32. [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
Quinteros A R; Fica C A; Abusada A N; Muñoz C L; Novoa M C; Gallardo A C
Rev Chilena Infectol; 2010 Feb; 27(1):25-33. PubMed ID: 20140311
[TBL] [Abstract][Full Text] [Related]
33. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
Dutta A; Palazzi DL
Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
[TBL] [Abstract][Full Text] [Related]
34. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
[TBL] [Abstract][Full Text] [Related]
35. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
36. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
37. Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020).
Chan JC; Dear J; Palm C; Reagan K
J Vet Intern Med; 2023; 37(3):1030-1037. PubMed ID: 37148178
[TBL] [Abstract][Full Text] [Related]
38. Nephrotoxicity associated with amphotericin B deoxycholate in neonates.
Le J; Adler-Shohet FC; Nguyen C; Lieberman JM
Pediatr Infect Dis J; 2009 Dec; 28(12):1061-3. PubMed ID: 19935267
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the safety and cost-effectiveness of nebulized liposomal amphotericin B and amphotericin B deoxycholate for antifungal prophylaxis after lung transplantation.
Umemura K; Katada Y; Nakagawa S; Hira D; Yutaka Y; Tanaka S; Ohsumi A; Nakajima D; Date H; Nagao M; Terada T
J Infect Chemother; 2024 Aug; 30(8):741-745. PubMed ID: 38354908
[TBL] [Abstract][Full Text] [Related]
40. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
